Compile Data Set for Download or QSAR
Report error Found 147 Enz. Inhib. hit(s) with all data for entry = 10834
LigandChemical structure of BindingDB Monomer ID 572169BDBM572169(US11478451, Example 24 | (rac)-4-chloro-3-ethyl-2,...)
Affinity DataIC50: 0.450nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572155BDBM572155((rac)-4-chloro-3-ethyl-1-[2-(morpholin-4-yl)ethyl]...)
Affinity DataIC50: 0.470nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572162BDBM572162(US11478451, Example 17 | (+)-4-chloro-7-{3-[(6-flu...)
Affinity DataIC50: 0.490nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572159BDBM572159((+)-4-chloro-2,3,14-trimethyl-7-[3-(naphthalen-1-y...)
Affinity DataIC50: 0.520nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572166BDBM572166(US11478451, Example 21 | (rac)-4-chloro-3-ethyl-2-...)
Affinity DataIC50: 0.590nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572181BDBM572181((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 0.590nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572152BDBM572152(US11478451, Example 7 | (rac)-4-chloro-3-ethyl-7-{...)
Affinity DataIC50: 0.600nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572161BDBM572161(US11478451, Example 16 | US11447504, Example 16 | ...)
Affinity DataIC50: 0.660nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572173BDBM572173(US11478451, Example 27 | US11447504, Example 27 | ...)
Affinity DataIC50: 0.690nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572219BDBM572219(US11447504, Example 76 | US11447504, Example 75 | ...)
Affinity DataIC50: 0.700nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572192BDBM572192(US11478451, Example 47 | (rac)-4-chloro-3-ethyl-14...)
Affinity DataIC50: 0.710nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572178BDBM572178(US11478451, Example 32 | (+)-4-chloro-7-{3-[(6-flu...)
Affinity DataIC50: 0.710nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572196BDBM572196((+)-4-chloro-3-methyl-2-[3-(4-methylpiperazin-1-yl...)
Affinity DataIC50: 0.75nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572184BDBM572184((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 0.780nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572186BDBM572186(US11478451, Example 41 | US11447504, Example 41 | ...)
Affinity DataIC50: 0.790nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572203BDBM572203(US11478451, Example 57 | 4-chloro-12,12-difluoro-2...)
Affinity DataIC50: 0.820nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572166BDBM572166(US11478451, Example 21 | (rac)-4-chloro-3-ethyl-2-...)
Affinity DataIC50: 0.850nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572199BDBM572199((+)-4-chloro-3-ethyl-2-methyl-7-{3-[(naphthalen-1-...)
Affinity DataIC50: 0.870nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572155BDBM572155((rac)-4-chloro-3-ethyl-1-[2-(morpholin-4-yl)ethyl]...)
Affinity DataIC50: 0.890nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572177BDBM572177(US11478451, Example 30 | (rac)-4-chloro-7-{3-[(6-f...)
Affinity DataIC50: 0.920nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572212BDBM572212(US11478451, Example 083 | (9aS,10aR or 9aR, 10aS)-...)
Affinity DataIC50: 0.920nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572183BDBM572183(US11478451, Example 069 | (rac)-4-chloro-3-ethyl-7...)
Affinity DataIC50: 0.940nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572216BDBM572216(US11447504, Example 72 | US11447504, Example 73 | ...)
Affinity DataIC50: 0.960nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572161BDBM572161(US11478451, Example 16 | US11447504, Example 16 | ...)
Affinity DataIC50: 1nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572149BDBM572149(US11478451, Example 4 | rac-4-chloro-1,3-dimethyl-...)
Affinity DataIC50: 1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572222BDBM572222(US11447504, Example 79 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572158BDBM572158(US11478451, Example 11 | (rac)-4-chloro-2,3,14-tri...)
Affinity DataIC50: 1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572225BDBM572225(US11447504, Example 82 | US11447504, Example 81 | ...)
Affinity DataIC50: 1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572152BDBM572152(US11478451, Example 7 | (rac)-4-chloro-3-ethyl-7-{...)
Affinity DataIC50: 1.20nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572166BDBM572166(US11478451, Example 21 | (rac)-4-chloro-3-ethyl-2-...)
Affinity DataIC50: 1.20nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572175BDBM572175(US11478451, Example 28 | (rac)-12-chloro-10,11-dim...)
Affinity DataIC50: 1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572186BDBM572186(US11478451, Example 41 | US11447504, Example 41 | ...)
Affinity DataIC50: 1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572219BDBM572219(US11447504, Example 76 | US11447504, Example 75 | ...)
Affinity DataIC50: 1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572165BDBM572165((rac)-(11 Z)-4-chloro-3-ethyl-2-methyl-7-[3-(napht...)
Affinity DataIC50: 1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572201BDBM572201(US11478451, Example 071 | (rac)-4-chloro-3-ethyl-7...)
Affinity DataIC50: 1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572192BDBM572192(US11478451, Example 47 | (rac)-4-chloro-3-ethyl-14...)
Affinity DataIC50: 1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572189BDBM572189(US11478451, Example 44 | (rac)-(11Z)-4-chloro-3-et...)
Affinity DataIC50: 1.40nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572176BDBM572176(US11478451, Example 29 | (rac)-12-chloro-7,10,11-t...)
Affinity DataIC50: 1.5nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572169BDBM572169(US11478451, Example 24 | (rac)-4-chloro-3-ethyl-2,...)
Affinity DataIC50: 1.5nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572205BDBM572205(US11478451, Example 60 | US11447504, Example 60 | ...)
Affinity DataIC50: 1.5nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572205BDBM572205(US11478451, Example 60 | US11447504, Example 60 | ...)
Affinity DataIC50: 1.5nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572210BDBM572210(US11478451, Example 081 | US11447504, Example 64 |...)
Affinity DataIC50: 1.5nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572149BDBM572149(US11478451, Example 4 | rac-4-chloro-1,3-dimethyl-...)
Affinity DataIC50: 1.60nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572212BDBM572212(US11478451, Example 083 | (9aS,10aR or 9aR, 10aS)-...)
Affinity DataIC50: 1.70nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572195BDBM572195(US11478451, Example 50 | (rac)-4-chloro-3-methyl-2...)
Affinity DataIC50: 1.70nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572180BDBM572180(US11478451, Example 35 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 1.70nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572228BDBM572228(US11447504, Example 85 | US11447504, Example 84 | ...)
Affinity DataIC50: 1.90nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572225BDBM572225(US11447504, Example 82 | US11447504, Example 81 | ...)
Affinity DataIC50: 2nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572222BDBM572222(US11447504, Example 79 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 2.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 572216BDBM572216(US11447504, Example 72 | US11447504, Example 73 | ...)
Affinity DataIC50: 2.20nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

Displayed 1 to 50 (of 147 total ) | Next | Last >>
Jump to: